Adam Feuerstein

TheStreet.com Senior Columnist

Before joining TheStreet.com in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
« Back
Page 1 of 403
Article

Biotech Stock Mailbag: FDA Playbook

By Adam Feuerstein

Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process.

06:01AM 11/20/09

Article

U.S. Sees Low Demand for BioCryst Flu Drug

By Adam Feuerstein

Peaking flu season could mean no need for further peramivir orders.

11:12AM 11/18/09

Article

Another Genzyme Drug Goes Kaboom: BioBuzz

By Adam Feuerstein

Company halts development of kidney disease drug following poor test results.

08:05AM 11/18/09

Article

Vivus Seeks Faster ED Drug: Biobuzz

By Adam Feuerstein

Company says ED drug met all goals in phase III study.

06:42AM 11/18/09

Article

Genzyme's Termeer: Worst Biotech CEO of '09

By Adam Feuerstein

Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009.

12:31PM 11/17/09

Article

InterMune Hep C Drug Hit With Liver Tox Worry: BioBuzz

By Adam Feuerstein

Safety monitors force change to mid-stage study of ITMN-191

09:11AM 11/17/09

Article

Poniard's CEO Pulls a Belichik: BioBuzz

By Adam Feuerstein

Risky late-game call puts Poniard in a deep financial hole.

11:59AM 11/16/09

Article

A Closer Look at Cardium's Wound-Healing Drug: BioBuzz

By Adam Feuerstein

Is it the drug or the gel that worked best in a phase II study?

10:51AM 11/16/09

Article

Cell Therapeutics Lavishes Free Stock on Execs: BioBuzz

By Adam Feuerstein

'Retention' bonus awarded to CEO Jim Bianco, his management team and directors.

09:23AM 11/16/09

Article

Poniard Cancer Drug Fails Pivotal Study: BioBuzz

By Adam Feuerstein

Lung cancer drug picoplatin doesn't prolong survival in phase III study.

07:22AM 11/16/09

« Back
Page 1 of 403
Dow Jones S&P 500 NASDAQ 10-Year Note
10,318.16 1,091.38 2,146.04 33.56
Oil *
77.53
DOWN
14.28
DOWN
3.52
DOWN
10.78
UP
0.07
10 Yr
3.36%
SPDR Gold
112.94
-0.14%
-0.32%
-0.50%
+0.21%
Data delayed 20 minutes

Brokerage Partners